iRhythm Technologies, Inc. (IRTC)
合理估值基本面
43
价格
$113.66
市值
$3.75B
第一部分 · 这家公司值多少
概览
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users
Its Preventice Solutions arm, acquired for $925 million, is the closest challenger to Zio in long-term continuous ECG patch monitoring in the United States.
Baxter owns Bardy Diagnostics, whose Carnation ambulatory monitor patch is prescribed for the same arrhythmia work-ups that Zio is used for.
GE HealthCare supplies the traditional 24-to-48-hour Holter monitors that hospitals and clinics can choose instead of sending a patient home with a Zio patch.
Through BioTelemetry, which it bought for $2.8 billion, Philips sells the wearable ECG patches and mobile cardiac telemetry services that compete directly with iRhythm's Zio for the same cardiologists and the same insurance reimbursement.
Medtronic's LINQ family of insertable cardiac monitors targets the same patients under investigation for atrial fibrillation and unexplained fainting, competing for the diagnostic referral before a Zio is ever prescribed.
This private US company sells the VitalPatch, a disposable ECG patch with AI arrhythmia detection sold to the same cardiology practices that buy Zio.
资产负债表与流动性
营收
$825M
最近12个月(截至2026/6/30)
净利润
$-14M
最近12个月(截至2026/6/30)
自由现金流
$35M
股东权益合计
$153M
负债合计
$867M
流动比率
3.85
利息覆盖率
1.89
债务/EBITDA
-
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$104.37
当前价格
$113.66
安全边际
-8.9%
公允价值区间
$67.84 - $140.89
所用估值方法之间的离散区间,并非经过统计校准的置信区间。
估算方法
估值指标
市盈率(P/E)
-
ROE
-29.2%
市净率(P/B)
20.14
P/FCF
96.12
毛利率
71.5%
ROIC
-2.2%
盈利能力雷达图
价值创造(经济护城河)
ROIC
-2.2%
WACC
10.5%
ROIC − WACC
-12.7 pp
ROIC 低于资本成本:公司每投入一美元都在毁灭价值。
基本面分析标准
通过(12)
- EPS shows upward trend
- Price CAGR 14.06%
- Gross Margin 71.5%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 23.0%
- Analyst Consensus 95% Buy
- Earnings Surprise avg 3463.2%
- Net Margin Trend -1.7% vs -14.1%
- Piotroski F-Score 6/9
未通过(10)
- ROIC -2.2%
- P/FCF 96.12
- P/B Ratio 20.14
- Debt/Equity ratio
- Operating Margin -3.0%
- CapEx intensity
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -9.0%
- Share Dilution 2.7%
不可用(5)
- Dividend Payout NaN%
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-评分
信号混杂:部分领域需关注
盈利质量
低质量:需深入审查会计处理
股权稀释
正在发行新股,稀释所有权
机构持股
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Mr. Quentin S. Blackford | President, CEO & Director | 46 |
| Mr. Daniel G. Wilson | CFO & Principal Financial Officer | 43 |
| Dr. Minang P. Turakhia M.D., M.S. | Chief Medical & Scientific Officer and Executive VP of Advanced Technologies | 51 |
| Mr. Patrick Michael Murphy J.D. | Chief Business & Legal Officer | 46 |
| Mr. Chad M. Patterson | Chief Commercial and Product Officer | 43 |
| Mr. Mervin Smith | Executive Vice President of Business Operations | 50 |
| Mr. Marc Rosenbaum | Senior VP of Finance & Chief Accounting Officer | 52 |
| Mr. Brian Lawrence | Executive VP & CTO | 55 |
| Ms. Lisa Pecora | Senior Vice President of Finance & Investor Relations | - |
| Mr. Sean Clinton Freeman | Executive Vice President of Strategy & Corporate Development | 49 |
审计风险
9
董事会风险
5
薪酬风险
3
股东权利风险
7
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。
损益历史
via SEC EDGAR
Latest News
Recent headlines for IRTC, sourced from Markets Gazette.
- 3d agoPOSITIVEJP Morgan forecasts a 20x revenue increase for this AI stock
JP Morgan has significantly boosted its outlook for US-listed iRhythm Technologies Inc. (IRTC), forecasting a remarkable 20-fold increase in the company's revenue by 2030. This optimistic projection is underpinned by the escalating demand for computing power and a concurrent rise in the pricing power of 'neocloud' companies like iRhythm. In a September note, the bank upgraded IRTC from 'Underweight' to 'Overweight', signaling strong conviction in its future growth trajectory. Investors should monitor iRhythm's ability to capitalize on this burgeoning market, as the forecast suggests substantial upside potential.
- 6/16/2026NEGATIVEiRhythm Investigates Cyber Incident After Hackers Claim Access To Sensitive Data
iRhythm Technologies is investigating a cybersecurity incident where hackers claim to have accessed sensitive patient and proprietary data. The breach reportedly occurred via third-party applications. While the company states it does not foresee a material impact on its operations or finances, any data breach involving patient information can lead to regulatory scrutiny, reputational damage, and potential legal liabilities. Investors will monitor the situation closely for any further developments or undisclosed consequences that could affect the company's long-term prospects and stock valuation.
via Markets Gazette